Ischemic cardiovascular involvement in psoriasis: A systematic review

International Journal of Cardiology

Volumn 178, Issue , 2015, Pages 191-199

  Mosca, Susanna ^a   Gargiulo, Paola ^b   Balato, Nicola ^a   Di Costanzo, Luisa ^a   Parente, Antonio ^a   Paolillo, Stefania ^a   Ayala, Fabio ^a   Trimarco, Bruno ^a   Crea, Filippo ^c   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Coronary artery disease; Inflammation; Psoriasis

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; BRIAKINUMAB; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETRETIN; ETRETINATE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12 INHIBITOR; INTERLEUKIN 23 INHIBITOR; IXEKIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OMEGA 3 FATTY ACID; PLACEBO; PROTEIN INHIBITOR; RETINOID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTI-INFLAMMATORY AGENTS;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIA; LOW DRUG DOSE; META ANALYSIS; PREVALENCE; PSORIASIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; METHODS; RISK FACTORS;

ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PSORIASIS; RISK FACTORS;

EID: 84916210950     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.092     Document Type: Review

References (58)

1. M.A. Lowes, A.M. Bowcock, and J.G. Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
2. V.E. Friedewald, J.C. Cather, J.M. Gelfand, K.B. Gordon, G.H. Gibbons, and S.M. Grundy AJC editor's consensus: psoriasis and coronary artery disease Am. J. Cardiol. 102 2008 1631 1643
3. J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, and X. Wang The risk of stroke in patients with psoriasis J. Invest. Dermatol. 129 2009 2411 2418
4. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
5. N.N. Mehta, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database Eur. Heart J. 31 2010 1000 1006
6. N.N. Mehta, Y. Yu, R. Pinnelas, P. Krishnamoorthy, D.B. Shin, and A.B. Troxel Attributable risk estimate of severe psoriasis on major cardiovascular events Am. J. Med. 124 2011 775 (e1-6)
7. S. Prodanovich, R.S. Kirsner, J.D. Kravetz, F. Ma, L. Martinez, and D.G. Federman Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality Arch. Dermatol. 145 2009 700 703
8. C.J. McDonald, and P. Calabresi Psoriasis and occlusive vascular disease Br. J. Dermatol. 99 1978 469 475
9. A.W. Armstrong, C.T. Harskamp, and E.J. Armstrong Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis JAMA Dermatol. 149 2013 84 91
10. A.W. Armstrong, C.T. Harskamp, and E.J. Armstrong The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies J. Hypertens. 31 2013 433 442 (discussion 42-3)
11. A.A. Qureshi, H.K. Choi, A.R. Setty, and G.C. Curhan Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses Arch. Dermatol. 145 2009 379 382
12. P. Rocha-Pereira, A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeira Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease Clin. Chim. Acta 303 2001 33 39
13. A.W. Armstrong, C.T. Harskamp, and E.J. Armstrong The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies Nutr. Diabetes 2 2012 e54
14. P. Gargiulo, F. Marsico, A. Parente, S. Paolillo, M. Cecere, and L. Casaretti Ischemic heart disease in systemic inflammatory diseases An appraisal. Int J Cardiol 170 3 2014 286 290
15. M.S. Tonetti, F. D'Aiuto, L. Nibali, A. Donald, C. Storry, and M. Parkar Treatment of periodontitis and endothelial function N. Engl. J. Med. 356 2007 911 920
16. P.M. Ridker Psoriasis, inflammation, and vascular risk: a problem more than skin deep? Eur. Heart J. 31 2010 902 904
17. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
18. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbe Incorporating variations in the quality of individual randomized trials into meta-analysis J. Clin. Epidemiol. 45 1992 255 265
19. C. Ma, C.T. Harskamp, E.J. Armstrong, and A.W. Armstrong The association between psoriasis and dyslipidaemia: a systematic review Br. J. Dermatol. 168 2013 486 495
20. D.H. Solomon, E. Massarotti, R. Garg, J. Liu, C. Canning, and S. Schneeweiss Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis JAMA 305 2011 2525 2531
21. K.B. Gordon, R.G. Langley, A.B. Gottlieb, K.A. Papp, G.G. Krueger, and B.E. Strober A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis J. Invest. Dermatol. 132 2012 304 314
22. B. Guida, A. Napoleone, R. Trio, A. Nastasi, N. Balato, and R. Laccetti Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial Clin. Nutr. 33 3 2014 399 405
23. D.D. Balci, A. Balci, S. Karazincir, E. Ucar, U. Iyigun, and F. Yalcin Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis J. Eur. Acad. Dermatol. Venereol. 23 2009 1 6
24. E. Osto, S. Piaserico, A. Maddalozzo, G. Forchetti, R. Montisci, and G. Famoso Impaired coronary flow reserve in young patients affected by severe psoriasis Atherosclerosis 221 2012 113 117
25. R.J. Ludwig, C. Herzog, A. Rostock, F.R. Ochsendorf, T.M. Zollner, and D. Thaci Psoriasis: a possible risk factor for development of coronary artery calcification Br. J. Dermatol. 156 2007 271 276
26. J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur. Heart J. 33 2012 1635 1701
27. F. Spah Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach Br. J. Dermatol. 159 Suppl. 2 2008 10 17
28. B.J. Nickoloff, H. Xin, F.O. Nestle, and J.Z. Qin The cytokine and chemokine network in psoriasis Clin. Dermatol. 25 2007 568 573
29. G. Liuzzo, F. Trotta, and D. Pedicino Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown Eur. Heart J. 34 2013 556 559
30. K. Ghoreschi, A. Laurence, X.P. Yang, K. Hirahara, and J.J. O'Shea T helper 17 cell heterogeneity and pathogenicity in autoimmune disease Trends Immunol. 32 2011 395 401
31. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N. Engl. J. Med. 352 2005 1685 1695
32. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
33. A.B. Alexandroff, M. Pauriah, R.D. Camp, C.C. Lang, A.D. Struthers, and D.J. Armstrong More than skin deep: atherosclerosis as a systemic manifestation of psoriasis Br. J. Dermatol. 161 2009 1 7
34. A.W. Armstrong, E.A. Brezinski, M.R. Follansbee, and E.J. Armstrong Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review Curr. Pharm. Des. 20 4 2014 500 512
35. S.J. Taler, S.C. Textor, V.J. Canzanello, and L. Schwartz Cyclosporin-induced hypertension: incidence, pathogenesis and management Drug Saf. 20 1999 437 449
36. N. Khalili, Z. Rostami, E. Kalantar, and B. Einollahi Hyperglycemia after renal transplantation: frequency and risk factors Nephrourol. Mon. 5 2013 753 757
37. M.J. Pereira, J. Palming, M. Rizell, M. Aureliano, E. Carvalho, and M.K. Svensson The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue Mol. Cell. Endocrinol. 365 2013 260 269
38. H.I. Katz, J. Waalen, and E.E. Leach Acitretin in psoriasis: an overview of adverse effects J. Am. Acad. Dermatol. 41 1999 S7 S12
39. P. Gisondi, S. Cazzaniga, S. Chimenti, A. Giannetti, M. Maccarone, and M. Picardo Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry J. Eur. Acad. Dermatol. Venereol. 27 2013 e30 e41
40. C.N. Ellis, N.A. Swanson, R.C. Grekin, N.G. Goldstein, D.R. Bassett, and T.F. Anderson Etretinate therapy causes increases in lipid levels in patients with psoriasis Arch. Dermatol. 118 1982 559 562
41. P. Sarzi-Puttini, M. Cazzola, B. Panni, M. Turiel, T. Fiorini, and N. Belai-Beyene Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis Rheumatol. Int. 21 2002 234 238
42. J. Dierkes, and S. Westphal Effect of drugs on homocysteine concentrations Semin. Vasc. Med. 5 2005 124 139
43. H. Refsum, S. Helland, and P.M. Ueland Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment Clin. Pharmacol. Ther. 46 1989 510 520
44. S. Prodanovich, F. Ma, J.R. Taylor, C. Pezon, T. Fasihi, and R.S. Kirsner Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis J. Am. Acad. Dermatol. 52 2005 262 267
45. B. Strober, C. Teller, P. Yamauchi, J.L. Miller, M. Hooper, and Y.C. Yang Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis Br. J. Dermatol. 159 2008 322 330
46. G. Avgerinou, D. Tousoulis, G. Siasos, E. Oikonomou, K. Maniatis, and N. Papageorgiou Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis Int. J. Cardiol. 151 2011 382 383
47. G. Mazzoccoli, I. Notarsanto, G.D. de Pinto, M.P. Dagostino, A. De Cata, and G. D'Alessandro Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients Intern. Emerg. Med. 5 2010 495 500
48. J.J. Wu, K.Y. Poon, J.C. Channual, and A.Y. Shen Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis Arch. Dermatol. 148 2012 1244 1250
49. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
50. L. Puig Cardiovascular risk and psoriasis: the role of biologic therapy Actas Dermosifiliogr. 103 2012 853 862
51. C. Ryan, C.L. Leonardi, J.G. Krueger, A.B. Kimball, B.E. Strober, and K.B. Gordon Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials JAMA 306 2011 864 871
52. K. Reich, R.G. Langley, M. Lebwohl, P. Szapary, C. Guzzo, and N. Yeilding Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies Br. J. Dermatol. 164 2011 862 872
53. T. Tzellos, A. Kyrgidis, and C.C. Zouboulis Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials J. Eur. Acad. Dermatol. Venereol. 27 2013 622 627
54. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, and E. Edson-Heredia Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N. Engl. J. Med. 366 2012 1190 1199
55. K.A. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, and G. Kricorian Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N. Engl. J. Med. 366 2012 1181 1189
56. T. Simon, S. Taleb, N. Danchin, L. Laurans, B. Rousseau, and S. Cattan Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction Eur. Heart J. 34 2013 570 577
57. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N. Engl. J. Med. 359 2008 2195 2207
58. B.M. Everett, A.D. Pradhan, D.H. Solomon, N. Paynter, J. Macfadyen, and E. Zaharris Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis Am. Heart J. 166 2013 199 207 (e15)